-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:
We lower our target price to $200 from $358, representing 24.9x our 2027 EPS forecast, below PODD's trailing-12-month average forward P/E of 55.02x. We lift our 2026 EPS estimate to $6.46 from $6.21 and our 2027 EPS to $8.04 from $7.93. Insulet shares were down ~9% on May 6 despite solid Q1 results beating expectations and raised guidance. Investors appear concerned about margin headwinds as adjusted gross margin was negatively impacted by over 150 bps from increased exit and obsolescence costs related to transitioning to new pod configurations. These concerns may be heightened by raw material and shipping cost increases from the Middle East conflict potentially pressuring gross margin for another quarter. However, PODD's Q1 showed strong financial execution and strategic progress with impressive 30% revenue growth balanced across geographies the U.S. grew 28% and international delivered standout 45% growth, indicating robust demand despite concerns that GLP-1s are shrinking the addressable market.